Format

Send to

Choose Destination
Thorax. 2018 Jun;73(6):565-574. doi: 10.1136/thoraxjnl-2017-210672. Epub 2018 Apr 13.

Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?

Author information

1
Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
2
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.

Abstract

COPD is characterised by tissue destruction and inflammation. Given the lack of curative treatments and the progressive nature of the disease, new treatments for COPD are highly relevant. In vitro cell culture and animal studies have demonstrated that mesenchymal stromal cells (MSCs) have the capacity to modify immune responses and to enhance tissue repair. These properties of MSCs provided a rationale to investigate their potential for treatment of a variety of diseases, including COPD. Preclinical models support the hypothesis that MSCs may have clinical efficacy in COPD. However, although clinical trials have demonstrated the safety of MSC treatment, thus far they have not provided evidence for MSC efficacy in the treatment of COPD. In this review, we discuss the rationale for MSC-based cell therapy in COPD, the main findings from in vitro and in vivo preclinical COPD model studies, clinical trials in patients with COPD and directions for further research.

KEYWORDS:

copd pathology; emphysema; innate immunity; lung proteases

PMID:
29653970
PMCID:
PMC5969341
DOI:
10.1136/thoraxjnl-2017-210672
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center